(R)-1-(4-(pentafluoro-λ⁶-sulfanyl)phenyl)ethan-1-amine | 1800248-22-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (R)-1-(4-(pentafluoro-λ⁶-sulfanyl)phenyl)ethan-1-amine
• 英文别名: (OC-6-21)-[4-[(1R)-1-Aminoethyl]phenyl]pentafluorosulfur；(1R)-1-[4-(pentafluoro-λ6-sulfanyl)phenyl]ethanamine
• CAS: 1800248-22-9
• 化学式: C₈H₁₀F₅NS
• 分子量: 247.232
• InChiKey: QAQRYPBLAZSOJE-ZCFIWIBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  27
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (R)-1-(4-(pentafluoro-λ⁶-sulfanyl)phenyl)ethan-1-amine 、 4-chloro-[1,2,4]triazolo[5,1-c][1,2,4]triazine 以 N-甲基吡咯烷酮 为溶剂， 反应 1.0h， 生成 N-{(1R)-1-[4-(pentafluoro-λ6-sulfanyl)phenyl]ethyl}[1,2,4]triazolo[5,1-c][1,2,4]triazin-4-amine
  参考文献：
  名称：

  [EN] SUBSTITUTED TRIAZOLO BICYCLICCOMPOUNDS AS PDE2 INHIBITORS
  [FR] BICYCLO-COMPOSÉS DE TRIAZOLE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE PDE2

  摘要：

  本发明涉及一种用于治疗与磷酸二酯酶2（PDE2）相关的中枢神经系统疾病的式（I）的取代三唑杂双环化合物，该化合物可用作治疗神经系统和精神疾病，如精神分裂症、精神病、帕金森病、帕金森病痴呆（PDD）或亨廷顿病，以及与纹状体功能不足或基底神经节功能障碍相关的化合物的用途。

  公开号：

  WO2017000277A1

文献信息

• CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
  申请人：Abbisko Therapeutics Co., Ltd.

  公开号：EP3964518A1

  公开（公告）日：2022-03-09

  A CD73 inhibitor having the structure represented by formula (I), a preparation method therefor and an application thereof. The series of compounds can be widely applied in the preparation of drugs for treating cancers or tumors that are at least partially mediated by CD73, autoimmune diseases and disorders and metabolic diseases, in particular drugs for treating melanoma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, leukemia, brain tumor, lymphoma, ovarian cancer and Kaposi's sarcoma. A new generation of CD73 inhibitor drugs is expected to be developed.

  一种具有公式(I)所表示结构的CD73抑制剂，其制备方法及其应用。该系列化合物可以广泛应用于制备用于治疗至少部分由CD73介导的癌症或肿瘤、自身免疫性疾病和紊乱以及代谢性疾病的药物，特别是用于治疗黑色素瘤、结肠癌、胰腺癌、乳腺癌、前列腺癌、肺癌、白血病、脑瘤、淋巴瘤、卵巢癌和卡波西肉瘤的药物。预计将开发出新一代的CD73抑制剂药物。
• Substituted triazolo bicyclic compounds as PDE2 inhibitors
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US10357481B2

  公开（公告）日：2019-07-23

  The present invention is directed to substituted triazolo bicyclic compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及式 I 的取代三唑并双环化合物，其可作为治疗剂用于治疗与磷酸二酯酶 2 (PDE2)相关的中枢神经系统疾病。本发明还涉及使用此类化合物治疗神经和精神疾病，如精神分裂症、精神病、帕金森病、帕金森病痴呆（PDD）或亨廷顿病，以及与纹状体功能低下或基底节功能障碍相关的疾病。
• SUBSTITUTED TRIAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS
  申请人：MORRIELLO Gregori J.

  公开号：US20180169072A1

  公开（公告）日：2018-06-21

  The present invention is directed to substituted triazolo bicyclic compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.